SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense volatility and social media discussion as the stock experiences a rapid, sentiment-driven revaluation amid a broader AI memory supercycle. Traders are debating whether the recent price action represents a sustainable structural shift in memory demand or a late-stage parabolic bubble, with the community closely tracking potential supply chain disruptions from labor negotiations in South Korea.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as traders weigh record-high equity valuations against geopolitical uncertainty in the Middle East and upcoming inflation data. The community is sharply divided, with bulls betting on persistent AI-driven momentum and market resilience, while bears argue that extreme RSI levels and parabolic technicals signal an imminent correction.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending due to intense investor speculation and a massive, parabolic rally fueled by the artificial intelligence "memory supercycle" and persistent NAND chip shortages. The community remains deeply divided between aggressive bulls targeting further highs and vocal bears who argue the stock is a bubble detached from fundamental reality, leading to highly volatile overnight trading patterns.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is facing significant volatility following a quarterly report that missed expectations due to margin pressures from its transition to branded weight-loss drugs. While the community is split between frustration over the earnings miss and optimism regarding raised full-year guidance and future peptide-related catalysts, traders are focused on how the platform's long-term pivot will impact its valuation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as retail investors grapple with extreme volatility and erosion from daily leverage decay during a historic, parabolic rally in the semiconductor sector. The community is sharply divided, with frustrated bears debating the viability of swing trading against a relentless AI-driven upward trend while others warn that the sector's valuation has entered dangerous, bubble-like territory.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as market participants speculate on the potential passage of the CLARITY Act, with community discussions heavily focused on upcoming Senate markup dates and the potential for institutional adoption. While some users express frustration over stagnant price action compared to other assets, many remain bullish, viewing current levels as an opportunity to accumulate before expected legislative clarity.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense retail and institutional engagement as investors speculate on the company's strategic positioning within the AI photonics and optical interconnect sector. The stock is currently experiencing high volatility and aggressive accumulation, with the community actively debating whether recent price swings represent a sustainable recovery or a speculative squeeze driven by options activity.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing high volatility following a first-quarter earnings report that missed revenue and EPS expectations, leading to a sharp after-hours decline. Despite the financial miss, community sentiment remains deeply divided between long-term investors focused on upcoming satellite launch catalysts and government contracts, and short-term traders reacting to the company's significant cash burn and execution hurdles.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing intense market activity as investors speculate on potential foundry deals with major tech partners, fueling heavy bullish sentiment despite heated debate over the stock's valuation. Community discussions are centered on institutional buying trends and the impact of government-backed semiconductor expansion initiatives, leading to significant volatility as bulls and bears clash over the sustainability of the current rally.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is trending due to significant momentum in the memory-chip sector and retail speculation linking the stock to emerging Edge AI infrastructure and potential gamma squeeze dynamics. Community sentiment remains highly polarized between bullish investors targeting triple-digit valuations based on growth potential and cautious traders warning of a volatile pump-and-dump cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues

Waters crushes Q1 2026 estimates as revenues surge 91.5%; newly acquired BD units top targets early, and 2026 guidance moves higher.


Altimmune (ALT) Projected to Post Earnings on Tuesday

Altimmune (NASDAQ:ALT) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-altimmune-inc-stock...

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead 

VKTX rose about 1.4% over the past month, beating Altimmune, Amgen, and Structure Therapeutics; however, Novo Nordisk led the pack with a 17.3% gain.

Equity

Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of "Moderate Buy" from Analysts

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and s...

<ul class="summary-bullets"><li>Lululemon shares dropped after the company announced a new CEO who will take over in September.&nbsp;</li><li>Lucid investors were concerned about financial stability, despite new funding and a change in CEO.</li><li>&nbsp;Altimmune shares fell after a $225 million stock offering to fund its Phase 3 MASH trial.&nbsp;</li></ul>Lululemon Athletica Inc. (LULU), Lucid Group Inc. (LCID), and Altimmune Inc. (ALT) tumbled to fresh lows on Thursday, reflecting growing skepticism toward once-favored growth narratives.The drop was driven by concerns over leadership uncertainty, financial strain and strategic direction. While&nbsp;<a href="https://stocktwits.com/symbol/LULU">Lululemon</a> and&nbsp;<a href="https://stocktwits.com/symbol/ALT">Altimmune</a> stock plummeted 13% and 16%, respectively,&nbsp; <a href="https://stocktwits.com/symbol/LCID">Lucid</a> tumbled over 9%.&nbsp;<h2 class="st-heading-2">LULU Faces Leadership Concerns</h2>Shares of Lululemon fell sharply after the company named a new CEO, set to take over in September. Investors reacted negatively to the delayed transition, particularly as North American sales showed signs of weakness.&nbsp;The leadership gap created uncertainty, prompting some shareholders to exit their positions rather than wait for a turnaround. The extended handover timeline has unsettled investors, who worry results could stay subdued until a new strategy takes shape. Many anticipate a quiet period before O’Neill steps in, with few major moves expected from interim co-CEOs Meghan Frank and André Maestrini.&nbsp;However, famed investor Michael Burry said he is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lulu-is-a-patience-trade-says-michael-burry-as-stock-dips-overnight-on-new-ceo-skepticism/cZBfmHQRebN">holding</a> his position in Lululemon and may buy more, noting it accounts for about 3.7% of his portfolio.&nbsp;<h2 class="st-heading-2">Lucid Struggles With Cash Burn</h2>Lucid’s stock hit record lows as investors focused on its financial health. Despite securing additional funding and appointing a new chief executive, concerns about ongoing losses and high production costs overshadowed optimism.&nbsp;Uber Technologies Inc. (UBER)&nbsp;earlier this week&nbsp;revealed it now owns roughly 37.75 million Lucid Class A shares, representing an 11.52% ownership position through a subsidiary. The filing confirms that Uber crossed the 10% threshold earlier this month, following a transaction completed on April 14, signaling deeper involvement between the two companies.<h2 class="st-heading-2">ALT Hit By Dilution Fears</h2>Altimmune also saw steep losses after announcing a large stock offering to fund clinical trials. The biotechnology firm, which is advancing its experimental treatment pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), announced details of its underwritten public offering on Thursday.&nbsp;Altimmune said the offering includes more than 64 million common shares, each paired with a warrant, priced at $3. The company expects to raise approximately $225 million in gross proceeds before expenses. Altimmune said it will direct the net funds toward its upcoming Phase 3 study in MASH.<h2 class="st-heading-2">What Are Retail Traders Saying?&nbsp;</h2>A Stocktwits user&nbsp;<a href="https://stocktwits.com/dumberdore/message/651231773">said</a> about Lucid, “Just the severe beating down is enough motivation for me to buy this stock at this price. I’m assuming just the parts and tech are worth more than the current market cap.”&nbsp;Commenting on Lululemon, another user said, “This company should just be sold if they can’t manage it better than this.”<stembedurl>https://stocktwits.com/StrayTrader/message/651234038</stembedurl>So far this year, LCID and LULU stocks have tanked by 40% and 31%, respectively, while ALT stock has sunk by 19%.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/penn-stock-slips-overnight-after-year-s-high-ceo-says-employment-matters-more-than-gas-prices-for-casino-visits/cZBWFQdReTJ">PENN Stock Slips Overnight After Year's High: CEO Says Employment Matters More Than Gas Prices For Casino Visits</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Lucid Group, Inc. is displayed on a smartphone screen, with a stock market chart in the background, on May 4, 2025. (Photo illustration by Cheng Xin/Getty Images)

LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? 

The decline was driven by concerns about factors ranging from leadership gaps and financial pressure to an unclear strategic direction. 

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.

<ul class="summary-bullets"><li>The offering is at a 13.5% discount to the stock’s closing price on Wednesday.</li><li>Altimmune plans to use the proceeds to support its Phase 3 trial of Pemvidutide in MASH, a liver disease.</li><li>The Phase 3 trial is expected to test multiple doses of Pemvidutide over 52 weeks.&nbsp;</li></ul>Shares of Altimmune Inc. (ALT) fell about 13% in pre-market trading on Thursday after the biotech company priced a $225 million public offering at a discount to its previous close, dampening investor sentiment.The company announced a public offering of roughly 64.3 million shares of common stock, along with warrants to purchase the same number of shares. Additionally, certain investors can opt for pre-funded warrants covering up to 10.75 million shares, each warrant paired with a common stock warrant. The combined offering price is set at $3 per share and accompanying warrant, or $2.999 for pre-funded warrant packages, Altimmune said.This represents a 13.5% discount to <a href="https://stocktwits.com/symbol/ALT">ALT stock’s</a> closing price of $3.47 on Wednesday.Altimmune plans to use the proceeds to support its Phase 3 trial of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease.Earlier in January, the firm announced a registered direct offering of about 17 million shares to raise around $75 million.<h2 class="st-heading-2">What’s The Status Of The Phase 3 Trial?</h2>In January, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for Pemvidutide. The designation is intended to accelerate the development and review of treatments that show strong early evidence of meaningful improvement over existing options. The company also confirmed alignment with the FDA on Phase 3 trial plans following its end-of-Phase 2 meeting.The Phase 3 trial is expected to test multiple doses of Pemvidutide over 52 weeks, using liver biopsy-based endpoints to potentially support quick approval. The company has also submitted a request for scientific advice from European regulators.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits changed to ‘neutral’ from ‘bullish’ a day earlier. The update saw message volumes on the platform increase by 182% over a 24-hour period.One reader called it a “horror story.”<stembedurl>https://stocktwits.com/Roaring_Capybara/message/651111776</stembedurl>Another user expects more dilution.<stembedurl>https://stocktwits.com/Charlie50/message/651108878</stembedurl>The stock has declined around 10% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dell-stock-record-high-evercore-price-target-raise/cZBBxE7Reb3">DELL Stock’s Sharp Rally Takes It To All-Time High – Evercore Flags Surging AI Demand And Long-Term Deal Momentum</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Dilution Fears Return: Why ALT Stock Is Getting Hit Again 

The biotech company priced a $225 million public offering at $3 per share, its second offering this year.

ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’

Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M

Altimmune (NASDAQ:ALT) shareholders approved all proposals presented at the company's virtual annual meeting on April 16, 2026, including the election of nine directors and amendments that expand the...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.24	--	--	N/A
Q4 '25	-$0.23	-$0.27	-15.38%	MISSED
Q3 '25	-$0.27	-$0.21	22.83%	BEAT
Q2 '25	-$0.34	-$0.27	19.70%	BEAT
Q1 '25	-$0.35	-$0.26	26.12%	BEAT

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest ALT News

ALTAltimmune Inc